Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: Role of differential histone acetylation on cAMP-regulated function

Molecular Pharmacology

Volumn 68, Issue 3, 2005, Pages 596-605

  Tilley, Douglas G ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOHEXIMIDE; FORSKOLIN; HISTONE; ISOPRENALINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE IV; RAP PROTEIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; EMBRYO; INTRON; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACETYLATION; ANIMALS; BASE SEQUENCE; CYCLIC AMP; DNA PRIMERS; HISTONES; INTRONS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; NIH 3T3 CELLS; PHENOTYPE; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR;

EID: 23944467322     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.014126     Document Type: Article

References (42)

1. 1 receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 36:364-370.
2. Anderson PG, Boerth NJ, Liu M, McNamara DB, Cornwell TL, and Lincoln TM (2000) Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol 20:2192-2197.
3. Baillie G, MacKenzie SJ, and Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 camp phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60:1100-1111.
4. Baillie GS, MacKenzie SJ, McPhee I, and Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131:811-819.
5. Bos JL (2003) Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4:733-738.
6. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
7. D'Sa C, Tolbert LM, Conti M, and Duman RS (2002) Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 81:745-757.
8. Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, and Maurice DH (2002) Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 61:1033-1040.
9. Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, Genieser HG, Doskeland SO, Blank JL, and Bos JL (2002) A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 4:901-906.
10. Erdogan S and Houslay MD (1997) Challenge of human jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in camp phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 321:165-175.
11. Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, and Bresnick EH (2000) Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc Natl Acad Sci USA 97:14494-14499.
12. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, et al. (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35:131-138.
13. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, and Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO (Eur Mol Biol Organ) J 18:893-903.
14. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18
15. Indolfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, Torella D, Caputo R, Ciardiello F, Tortora G, et al. (2000) 8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 36:288-293.
16. Indolfi C, Mongiardo A, Curcio A, and Torella D (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 13:142-148.
17. Kohout TA and Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18.
18. Kumar MS and Owens GK (2003) Combinatorial control of smooth muscle-specific gene expression. Arterioscler Thromb Vasc Biol 23:737-747.
19. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 277:35980-35989.
20. Li S, Sims S, Jiao Y, Chow LH, and Pickering JG (1999) Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ Res 85:338-348.
21. Liu H and Maurice DH (1999) Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274:10557-10565.
22. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, and Maurice DH (2000) Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615-26624.
23. Manabe I and Owens GK (2001) Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel p19-derived in vitro smooth muscle differentiation system. Circ Res 88:1127-1134.
24. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, and Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533-546.
25. Mehats C, Tanguy G, Dallot E, Cabrol D, Ferre F, and Leroy MJ (2001) Is upregulation of phosphodiesterase 4 activity by PGE2 involved in the desensitization of beta-mimetics in late pregnancy human myometrium? J Clin Endocrinol Metab 86:5358-5365.
26. Mehats C, Tanguy G, Dallot E, Robert B, Rebourcet R, Ferre F, and Leroy MJ (1999) Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 140:3228-3237.
27. Obara Y, Labudda K, Dillon TJ, and Stork PJ (2004) PKA Phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells. J Cell Sci 117:6085-6094.
28. Oger S, Mehats C, Dallot E, Ferre F, and Leroy MJ (2002) Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3′,5′- monophosphate-dependent pathway. J Clin Endocrinol Metab 87:5524-5531.
29. Owens GK, Kumar MS, and Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767-801.
30. Palmer D and Maurice DH (2000) Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58:247-252.
31. Palmer D, Tsoi K, and Maurice DH (1998) Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 82:852-861.
32. Rangarajan S, Enserink JM, Kuiperij HB, de Rooij J, Price LS, Schwede F, and Bos JL (2003) Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J Cell Biol 160:487-493.
33. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, Huston E, Sullivan M, and Houslay MD (2001) Molecular cloning, genomic positioning, promoter identification and characterization of the novel cyclic AMP-specific phosphodiesterase PDE4A10. Mol Pharmacol 59:996-1011.
34. Rose RJ, Liu H, Palmer D, and Maurice DH (1997) Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 122:233-240.
35. Rybalkin SD, Rybalkina I, Beavo JA, and Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151-157.
36. Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM, and Giembycz MA (1998) Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2 and 4D3 in jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in β2-adrenoreceptor desensitization. J Biol Chem 273:20575-20588.
37. Shepherd MC, Baillie GS, Stirling DI, and Houslay MD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 Cells. Br J Pharmacol 142:339-351.
38. Tilley DG and Maurice DH (2002) Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 62:497-506.
39. Verghese MW, McConnell RT, Lenhard JM, Hamacher L, and Jin SL (1995) regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 47:1164-1171.
40. Vicini E and Conti M (1997) Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 11:839-850.
41. Wong W and Scott JD (2004) AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5:959-970.
42. 3H]rolipram. J Pharmacol Exp Ther 305:565-572.